Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Healthcare

ZimVie Shareholders Approve Acquisition, Set for October Delisting

Dieter Jaworski by Dieter Jaworski
October 12, 2025
in Healthcare, Mergers & Acquisitions, Pharma & Biotech
0
ZimVie Stock
0
SHARES
36
VIEWS
Share on FacebookShare on Twitter

ZimVie Inc. is poised to conclude its tenure as a publicly traded entity after shareholders formally approved its acquisition by private equity firm ARCHIMED. The transaction, scheduled for completion on October 20, has now cleared its final significant obstacle.

Investors will receive $19.00 per common share in cash, representing a substantial premium of approximately 99% over the stock’s 90-day average trading price prior to the acquisition announcement. This values the entire company at around $730 million.

Exceptional Returns for Equity Holders

The $19.00 per share purchase price notably exceeds the average analyst price target of $17.75. Market observers had maintained a cautious stance toward the stock, with five analysts most recently issuing “reduce” recommendations. ARCHIMED’s offer, however, delivers an unexpectedly favorable outcome for shareholders.

Following the transaction’s finalization, ZimVie shares will be delisted from the Nasdaq Global Select Market, marking the company’s transition to private ownership.

Should investors sell immediately? Or is it worth buying ZimVie?

Strategic Transformation Culminates in Buyout

This acquisition represents the culmination of an extended strategic repositioning for the company. Earlier this year, in April 2024, ZimVie divested its spine business to H.I.G. Capital for $375 million, subsequently focusing exclusively on its dental implant operations.

Recent corporate activities had signaled the impending takeover. The company withdrew its annual guidance in July and canceled its earnings presentation. Their most recent quarterly report disclosed revenue of $116.7 million and adjusted earnings per share of $0.26.

Final Steps Toward Completion

With shareholder approval secured, only standard closing conditions remain before the October 20 finalization. For investors, this means they will receive their cash consideration within days while bidding farewell to ZimVie as a publicly traded security.

Ad

ZimVie Stock: Buy or Sell?! New ZimVie Analysis from January 11 delivers the answer:

The latest ZimVie figures speak for themselves: Urgent action needed for ZimVie investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 11.

ZimVie: Buy or sell? Read more here...

Tags: ZimVie
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Eli Lilly Stock
AI & Quantum Computing

Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

January 11, 2026
Viking Therapeutics Stock
Analysis

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

January 11, 2026
Netflix Stock
Analysis

Netflix Shares Under Pressure Amid High-Stakes Acquisition Battle

January 11, 2026
Next Post
Rocket Lab USA Stock

Space Sector Surge Continues as Rocket Lab Gains Momentum

American Tower Stock

American Tower Faces Critical Test Ahead of Quarterly Earnings

MP Materials Stock

Rare Earths Showdown: How China's Export Curbs Fuel MP Materials' Ascent

Recommended

Biotechnology Market Capitalization

Analyst Upgrades Price Target for Nuvation Bio to 5

2 years ago
CryoLife Stock

Medical Device Specialist Artivion Maintains Strong Analyst Backing

3 months ago
Walgreens Boots Alliance Stock

Walgreens Concludes Public Trading Era Following Landmark Acquisition

3 months ago
MA stock news

Analysis of Short Interest and Financial Performance of US Bancorp

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Procter & Gamble Shares Approach a Critical Juncture

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

Palantir Shares: A Wall Street Divide and a Bold New Price Target

Trending

Eli Lilly Stock
AI & Quantum Computing

Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

by Felix Baarz
January 11, 2026
0

Eli Lilly and Company has opened 2026 with a clear strategic push to diversify and strengthen its...

Alibaba Stock

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

January 11, 2026
Vulcan Energy Stock

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

January 11, 2026
Viking Therapeutics Stock

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

January 11, 2026
Astera Labs Stock

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances
  • Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs
  • Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com